Varian Medical Systems — Q2 FY2020 Earnings Presentation
36 slides from Varian Medical Systems's earnings presentation, May 4, 2020

Slide 1: Second Quarter Fiscal Year 2020
Second Quarter Fiscal Year 2020 May 4, 2020 Investor Relations

Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. S

Slide 3: Agenda Q2 FY 2020 earnings
Agenda Q2 FY 2020 earnings 1. Second Quarter Results 2. Total Company Performance 3. Segment Performance 4. Appendix VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

Slide 4: Overview
Overview

Slide 5: Q2 FY 2020 key financial metrics
Q2 FY 2020 key financial metrics $M Q2 Y/Y • Orders and revenues growth reflect the spread Oncology Orders1 $773 1% of COVID-19 across the globe Revenues $794 2% Oncology $761 2% • Subsequent to March 9 announcement, Proton Solutions $22 (32%) Americas and EMEA revenues were impacted Other $12 n/a b

Slide 6: Long-term growth and value creation strategy
Long-term growth and value creation strategy Focusing on these Strategic enablers will deliver core business growth, global expansion and new opportunities Innovate in radiation therapy Leverage artificial intelligence, machine learning and Global Leader cloud solutions Global Leader in in Radiation

Slide 7: Executing on long-term growth strategy
Executing on long-term growth strategy Innovate Leverage Grow Artificial Intelligence, Machine Learning, Emerging Geographies, Businesses and in Radiation Therapy and Cloud Solutions Technologies KEY METRICS KEY METRICS KEY ACCOMPLISHMENTS • Global market leader • Software revenues grew +7% • CTSI a

Slide 8: Varian linac net installed base
Varian linac net installed base Installed base growth 8,634 Varian strengthened its global leadership in radiation therapy • Net installed base grew +4% or 342 units, driving +342 future recurring software and services revenues (+4%) • Installed base grew across all three geographies 8,292 Q2 FY19 Q

Slide 9: Key wins
Key wins Americas EMEA APAC Ascension Health Partners Healthcare Australia – Icon Group Thailand 5 TrueBeam systems with 5 TrueBeam, 1 Edge, and 2 Russia 1 Ethos upgrade 1st Ethos multiple upgrades Ethos system Pharma Standard 12 TrueBeam, 22 Halcyon and 1 VitalBeam Lapino Clinical Hospital 1 TrueBe

Slide 10: Total Company Performance
Total Company Performance varian

Slide 11: Total company results (GAAP)
Total company results (GAAP) Key P&L financial metrics • Orders and revenues growth reflects the spread of COVID-19 across the globe VARIAN • Revenues driven by strong growth in software and $M Q2 FY20 Y/Y TTM Y/Y services Gross Orders $846 10% $3,741 12% • Gross Margin rate up in the quarter driven

Slide 12: Total company results (non-GAAP)
Total company results (non-GAAP) Key P&L financial metrics • Orders and revenues growth reflects the spread of COVID-19 across the globe VARIAN • Revenues driven by strong growth in software and $M Q2 FY20 Y/Y TTM Y/Y services; Organic revenues down 1% Gross Orders $846 10% $3,741 12% • Gross Margin

Slide 13: Strong financial position
Strong financial position Key balance sheet and cash flow metrics Strong balance sheet with total accessible Cash & Cash Equivalents ($M) Cash Flow from Operations ($M) liquidity of $1.3 billion +22% Y/Y +$35M Y/Y $800 $200 $150 $700 • Cash & Cash equivalents of $668 million $100 $600 $50 • $661 mil

Slide 14: Revenue visibility drivers
Revenue visibility drivers Services revenue mix & product backlog 100% $3,500 • Services revenues (e.g. recurring-like revenues, $3,000 hardware services and software service agreements) increasing as percent of total revenues stream $2,500 • Oncology orders and backlog remains a relevant leading in

Slide 15: Capital allocation priorities
Capital allocation priorities Evaluating investment opportunities with discipline necessary in this environment Long-term value creation strategy that includes balancing growth, profitability and liquidity Q2 updateMaintain • Maintain financial flexibility to navigate through economic environment an

Slide 16: Segment Performance
Segment Performance varian

Slide 17: Oncology Systems segment (GAAP)
Oncology Systems segment (GAAP) Key financial metrics VARIAN • Gross Orders and Revenues growth reflects the $M Q2 FY20 Y/Y TTM Y/Y progression of COVID-19 across the globe Gross Orders $773 1% $3,462 5% Revenues $761 2% $3,155 10% • Gross Orders in the quarter grew 1% in dollars and 5% over the tra

Slide 18: Oncology Systems gross orders by geography
Oncology Systems gross orders by geography APAC AMERICAS -5% Q2 Y/Y -3% Q2 Y/Y1 (-5% cc) (-3% cc) -2% TTM Y/Y +4% TTM Y/Y1 (-1% cc) (+4% cc) (1) In North America, Q2 orders growth of -1% and TTM orders growth of +3% EMEA +11% Q2 Y/Y (+13% cc) +9% TTM Y/Y 18 (+12% cc)

Slide 19: Proton Solutions segment (GAAP)
Proton Solutions segment (GAAP) Key financial metrics VARIAN • Gross Orders and Revenues growth reflects the $M Q2 FY20 Y/Y TTM Y/Y progression of COVID-19 across the globe Gross Orders $61 1,206% $229 1,076% Revenues $22 (32%) $123 (23%) • Awarded 2 Orders in the APAC region Product $15 (48%) $96 (

Slide 20: ProBeam proton therapy system sites
ProBeam proton therapy system sites 26 78 ProBeam Total Sites Rooms 12 39 Operational Operational Operational Centers Centers Under Development Sites Rooms1 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 20

Slide 21: Other segment (GAAP)
Other segment (GAAP) Key financial metrics VARIAN • Gross Orders and Revenues growth reflects the $M Q2 FY20 Y/Y TTM Y/Y progression of COVID-19 across the globe Gross Orders $12 n/a $50 n/a Revenues $12 n/a $50 n/a • Revenues from Interventional Oncology business represent sales for cryoablation, e

Slide 22: In summary, we are…
In summary, we are… Global leader in radiation therapy Growing our net installed base driving future recurring …Driving software and services revenues toward our vision Expanding into high growth, high margin businesses of a world without fear of cancer Winning in emerging markets with our strong va

Slide 23: Appendix
Appendix

Slide 24: Machine Utilization Trends
Machine Utilization Trends CHINA New Year Lockdown • Cancer treatment is not considered an elective 100% 106% procedure • Volume impact from COVID-19 has varied by geography • In China, RT is an in patient procedure and thus saw a decline more dramatic than U.S. UNITED STATES − As the outbreak was c

Slide 25: Non-GAAP disclosure
Non-GAAP disclosure Discussion of Non-GAAP Financial Measures This presentation includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: organic revenue growth, non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per

Slide 26: Organic revenue growth reconciliation
Organic revenue growth reconciliation $M 2Q FY19 2Q FY20 Percent Change Impact from Impact from Organic Growth Acquisitions Foreign Exchange Total Revenues $779.4 $794.5 2 % (4)% 1% (1) % $M 1Q FY19 1Q FY20 Percent Change Impact from Impact from Organic Growth Acquisitions Foreign Exchange Total Rev

Slide 27: GAAP to non-GAAP reconciliation
GAAP to non-GAAP reconciliation THE FOLLOWING TABLE RECONCILES GAAP AND NON-GAAP FINANCIAL MEASURES 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 Dollars and shares in millions, except per share amounts Non-GAAP adjustments Amortization of intangible assets and inventory step-up (1) $6.1 $6.8 $20.0 $9.8 $

Slide 28: Total revenues by sales classification
Total revenues by sales classification $M 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 Product revenues $430.5 $461.3 $492.1 $421.0 $407.3 Y/Y 9 % 26 % 10 % 5 % (5)% Service revenues $348.9 $364.5 $386.8 $407.9 $387.2 Y/Y 4 % 6 % 9 % 20 % 11 % Total revenues $779.4 $825.8 $878.9 $828.9 $794.5 Y/Y 7 % 16

Slide 29: Total revenues by product type
Total revenues by product type $M 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 2Q Y/Y Hardware $367.0 $387.9 $430.2 $359.0 $340.9 (7)% Oncology Systems $339.1 $361.7 $379.2 $320.0 $316.1 (7)% Proton Solutions $27.9 $24.2 $33.6 $20.1 $13.1 (53)% Other — $2.0 $17.4 $18.9 $11.7 n/a Software1 $144.2 $155.7 $

Slide 30: Total revenues by region
Total revenues by region $M 2Q FY19 3Q FY19 4QFY19 1Q FY20 2Q FY20 Americas revenues $371.3 $401.2 $404.5 $402.2 $387.9 Y/Y 9 % 17 % 2 % 15 % 4 % Y/Y – CC 10 % 17 % 2 % 15 % 5 % EMEA revenues $261.5 $271.3 $289.6 $272.9 $250.9 Y/Y 3 % 18 % 9 % 9 % (4)% Y/Y – CC 10 % 24 % 12 % 11 % (2)% APAC revenues

Slide 31: Total Oncology Systems revenues by sales classification
Total Oncology Systems revenues by sales classification $M 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 Product revenues $402.6 $433.8 $439.4 $382.0 $381.0 Y/Y 11 % 33 % 9 % 4 % (5)% Y/Y – CC 14 % 36 % 10 % 5 % (4)% Service revenues $344.2 $359.1 $380.2 $400.4 $379.5 Y/Y 3 % 6 % 8 % 19 % 10 % Y/Y – CC 6

Slide 32: Total Oncology Systems revenues by region
Total Oncology Systems revenues by region $M 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 Americas revenues $357.1 $385.6 $377.8 $378.9 $369.7 Y/Y 11 % 19 % 2 % 15 % 4 % Y/Y – CC 12 % 20 % 2 % 15 % 4 % EMEA revenues $245.3 $256.4 $264.7 $259.8 $240.9 Y/Y 2 % 23 % 6 % 11 % (2)% Y/Y – CC 9 % 30 % 9 % 13 %

Slide 33: Total Proton Solutions revenues by sales classification
Total Proton Solutions revenues by sales classification $M 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 Product revenues $27.9 $25.5 $35.3 $20.1 $14.6 Y/Y (7)% (33)% (19)% (40)% (48)% Service revenues $4.7 $5.4 $6.6 $7.5 $7.7 Y/Y 151% 44 % 157 % 54 % 61 % Total revenues $32.6 $30.9 $41.9 $27.6 $22.3 Y/Y

Slide 34: Oncology Systems gross orders by region
Oncology Systems gross orders by region $M 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 Americas orders $366.1 $357.4 $559.0 $359.5 $355.4 Y/Y 7 % (1)% 11 % 7 % (3)% Y/Y – CC 8 % (1)% 11 % 7 % (3)% EMEA orders $233.3 $281.1 $395.9 $236.7 $259.3 Y/Y 17 % 8 % 10 % 8 % 11 % Y/Y – CC 25 % 13 % 12 % 11 % 13 %

Slide 35: Condensed consolidated statements of cash flows
Condensed consolidated statements of cash flows $M 2Q FY19 3Q FY19 4Q FY19 1Q FY20 2Q FY20 Net cash provided by (used in) Operating Activities $(13.4) $126.5 $117.8 $112.6 $21.9 Net earnings 88.4 29.5 70.4 88.9 43.1 Share-based compensation expense 12.5 12.2 12.7 14.9 11.3 Depreciation 13.0 12.9 15.

Slide 36: Our promise
Our promise People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer. W
Source: SEC EDGAR · 8-K filed May 4, 2020
More decks from Varian Medical Systems Inc
Q1 FY2021 Earnings Presentation29 slides · Jan 26, 2021
Q4 FY2020 Earnings Presentation30 slides · Oct 27, 2020
Merger or Acquisition (August 2020)33 slides · Aug 4, 2020
Merger or Acquisition (August 2020)18 slides · Aug 3, 2020
Q3 FY2020 Earnings Presentation36 slides · Aug 3, 2020
Q1 FY2020 Earnings Presentation35 slides · Jan 29, 2020